Evidence map›Paper›PMID 42512346›Full record

ArticleCancers2026

Optimized Test Utilization Significantly Increased the Positive Detection Rate for Myeloproliferative Neoplasms.

Landry E Nfonsam, Melody Zhenchen Qi, Darci T Butcher, Clinton J V Campbell, Amanda Cocca, Shreyash Dalmia, Gwynivere A Davies, Betty-Ann Hohenadel, Elizabeth McCready

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Landry E NfonsamHamilton Regional Laboratory Medicine Program, Hamilton Health Sciences, Hamilton, ON L8V 1C3, Canada.
Melody Zhenchen QiBiology and Pharmacology Co-Op Program, McMaster University, Hamilton, ON L8S 4L8, Canada.
Darci T ButcherHamilton Regional Laboratory Medicine Program, Hamilton Health Sciences, Hamilton, ON L8V 1C3, Canada.
Clinton J V CampbellHamilton Regional Laboratory Medicine Program, Hamilton Health Sciences, Hamilton, ON L8V 1C3, Canada.
Amanda CoccaHamilton Regional Laboratory Medicine Program, Hamilton Health Sciences, Hamilton, ON L8V 1C3, Canada.
Shreyash DalmiaDepartment of Oncology, McMaster University, Hamilton, ON L8S 4L8, Canada.ORCID 0000-0001-8310-8452
Gwynivere A DaviesDepartment of Oncology, McMaster University, Hamilton, ON L8S 4L8, Canada.
Betty-Ann HohenadelHamilton Regional Laboratory Medicine Program, Hamilton Health Sciences, Hamilton, ON L8V 1C3, Canada.
Elizabeth McCreadyHamilton Regional Laboratory Medicine Program, Hamilton Health Sciences, Hamilton, ON L8V 1C3, Canada.ORCID 0000-0002-7952-2279

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMolecular testing for myeloproliferative neoplasms (MPNs) without defined clinical criteria can lead to inefficient laboratory utilization without proportional diagnostic benefit.

methodsWe evaluated the impact of implementing clinical acceptance criteria, including unexplained abnormal blood counts, unusual-site thrombosis, unexplained hepatosplenomegaly, and/or leukoerythroblastic blood film for gene (

resultsOur results show that test volumes decreased significantly from 1835 in the pre-implementation period to 1050 post-implementation, while the positivity rate increased from 12% to 17% (χ

conclusionsThese findings show that implementing appropriate pre-test clinical criteria significantly improved MPN test utilization and diagnostic yield.

Indexed as

BCR::ABL1CALRdiagnostic testingJAK2MPLmyeloproliferative neoplasmtest utilization

Identifiers

PMID42512346
PMCPMC13406408

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.